There is good news for men who routinely use Viagra to treat erection problems: Since Viagra came off patent, the generic form, sildenafil, made by legitimate drug manufactures, has been becoming widely available at lower and lower prices.

This is a godsend, because Viagra originally cost $60 a pill, making it unaffordable for huge numbers of men who could have been helped by it.

Medicare used to allow only four pills a month. So if you weren’t rolling in money, Medicare essentially was rationing sex for couples in which an older man was suffering with ED.

For many years, Viagra has been the most counterfeited drug in the world. But many of the phony versions available online were adulterated with dangerous substances such rat poison or blue ink, so it was dangerous to be taking them. Now you can buy legitimate sildenafil for much less.

Even when the original patent expired, drug manufactures kept the prices for the little blue pill high — around $30 a pill in December of 2017.

But now that many respected manufacturers are making sildenafil, the prices have gone down dramatically.

If you take sildenafil, do some investigation of costs through different pharmacies and services. For instance, getting the drug through your regular pharmacy.

The lowest WEMAILMD.COM price for the most common version of sildenafil 100 mg is 300 pills for around $120.

An estimated six to 15 million people in the U.S. are children born of a pregnancy complicated by preeclampsia. New research performed in rats reveals that treating preeclampsia with sildenafil citrate (Viagra) may help protect the cardiovascular health of the offspring.

The Research Insights has as of late declared the addition of another research report to its developing repository. The exploration report, titled “Global Sildenafil Drug Market Report,” offers an unmistakable understanding of the subject matter. Understood from the title of the publication, the 2019–2025 forecast period considered here has been kept in view to foresee the overall revenue, price, consumption by country, and sales by type and application of the market.

Sildenafil, sold as the brand name Viagra among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is unclear if it is effective for treating sexual dysfunction in women. It is taken by mouth or injection into a vein. The Sildenafil drug market is predictable to grow exponentially during the estimated period due to increasing prevalence as well as incidence of erectile dysfunction and rising aging population globally. The petition for the treatment of erectile dysfunction is increasing due to more incidences of severe disease, rising awareness, and patient education.

Request for Sample Copy of this report@:

https://www.theresearchinsights.com/request_sample.php?id=10418     

Top Companies

Pfizer, Lupin Laboratories, Unichem Laboratories, Torrent Pharmaceuticals, Alembic Chemical, Sandoz, Osho Pharma, and Atlas Laboratories Pvt Ltd.

Tadalafil (Cialis) is one of the most popular erectile dysfunction (ED) drugs. Its major appeal? The drug comes in low-dose versions that can be taken daily. This means you can have sex at any time, rather than needing to take a pill from time to time as needed like other ED brands.

The starting dose for daily-use Cialis is 2.5 milligrams (mg). If that doesn’t work, you can increase your daily dose up to 5 mg. But is this the right approach for you—or are you better off with traditional ED drugs like Viagra, Levitra, or even the nondaily version of Cialis? If you are contemplating Cialis for daily use, consider these questions and then discuss it with your doctor:

• How often do you have sex? If it’s two or more times a week, a daily pill might be a reasonable choice, since the drug continually circulates in your bloodstream.
• How important is spontaneity? A daily pill clears the path for sex at any time—if the drug works for you. (Remember, just like other ED drugs, it may not work for everyone). On the other hand, the 36-hour window offered by the nondaily version of Cialis might offer enough spontaneity.
• Have side effects of your current ED pill been bothering you? Taking a daily low-dose pill may reduce side effects, though it may reduce effectiveness as well. In studies, the most common daily pill side effects were headache, muscle pain, indigestion, and back pain.
• How much alcohol do you drink? Men taking Cialis for daily use can experience a worrisome drop in blood pressure if they drink too much.
• What other medications do you take? Ask your doctor if any medications or supplements you take might interact with a daily erectile dysfunction pill, including blood pressure drugs, antifungal drugs, and HIV drugs. Also, men taking nitrate medications are advised not to take any ED drugs.
• How important is cost? While the manufacturer suggests that a 30-day supply of daily Cialis should cost about the same as eight pills of 36-hour Cialis a month, there’s no way to enforce this. Check your insurance policy and local pharmacies for price information.

– By Matthew Solan
Executive Editor, Harvard Men’s Health Watch

Cialis increases blood flow to the penis, and this enables a man to achieve an erection. It does not lead to sexual arousal. It should be used with caution, and only under medical supervision.

Tadalafil was approved by the United States (U.S.) Food and Drug Administration (FDA) in 2003 for the treatment of erectile dysfunction (ED). It is also used to treat pulmonary arterial hypertension and benign prostatic hyperplasia, a condition in which the prostate gland becomes enlarged, causing problems with urination.

Daily tadalafil has the potential to be a treatment option for Peyronie’s disease (PD), according to data presented at the Sexual Medicine Society of North America 18^th Annual Fall Scientific Meeting in San Antonio, Texas.

In a small study of PD patients, treatment with the drug, a phosphodiesterase type 5 (PDE5) inhibitor that is FDA approved for treating erectile dysfunction, was associated with decreased pain on erection and degree of penile curvature and improved erectile function.

Consumers, especially men, should not purchase or use two e-cigarette liquids that contain popular erectile dysfunction drugs, the Food and Drug Administration warned Tuesday.

The two HelloCig e-liquids contain tadalafil and sildenafil, the main ingredients in two of the most popular male enhancement drugs on the market, the FDA said. “These FDA-approved prescription drugs are not approved for inclusion in e-liquid products sold over the counter and are therefore being sold illegally.”

By not properly labeling the e-liquids, the agency said, the company was not providing adequate warnings for the protection of users, specifically anyone with erectile dysfunction, high blood pressure, diabetes, high cholesterol or heart disease who take nitrates to manage their condition.

“These undeclared ingredients may interact with nitrates found in some prescription drugs such as nitroglycerin and may lower blood pressure to dangerous levels,”  the FDA said in its warning .

A lab analysis found both sildenafil and tadalafil in E-Cialis HelloCig E-Liquid and sildenafil in E-Rimonabant HelloCig E-Liquid, both sold by Shanghai-based HelloCig Electronic Technology Co. Ltd.

The company has not responded to a request for comment.

Although no adverse events have been reported to the agency, all consumers should stop using the products immediately, the FDA said, and anyone who experiences side effects  should report them  to the FDA’s MedWatch Adverse Event Reporting program.

The FDA says it sent a  warning letter  to HelloCig in October, citing a number of concerns about illegal marketing claims. HelloCig was misbranding and selling its products in the United States as an “FDA approved product with FDA,” in violation of federal rules.

“FDA recently warned HelloCig of these issues and contacted the company several times to recommend they recall these products due to the risks to consumers. However, HelloCig has not responded to the agency’s recommendation,” the agency said in its warning.

Bottles of E-Cialis HelloCig E-Liquid were sold with an image of a Cialis bottle and tablets, while advertisements on Twitter and Tumbir showed “a partially undressed couple embracing,” the FDA says. The caption states, “WOOOOW, Have you tried our E-Cialis? It is amazing LOL.”

Though E-Rimonabant HelloCig E-Liquid contains the same active ingredient as Viagra, the FDA said HelloCig was marketing it with an image of an Acomplia container and tablets.

“Acomplia is the tradename of the anti-obesity drug product in Europe,” the FDA warned. “Using the tradename of the drug product Acomplia and including an image of the Acomplia container and tablets next to the product on your website suggests that the product is intended to treat obesity.”

HelloCig did not respond to the initial warning, the FDA said.

The manufacturers of Cialis has not responded to requests for comment. The maker of Viagra had no comment.

adalafil (Cialis®) was originally developed by Lilly ICOS, LLC –a longer lasting alternative to Sildenafil Citrate (Viagra®) and is indicated for the treatment of erectile dysfunction (ED) in adult males. Tadalafil is facing imminent patent expiration.

Whilst Cialis® is a long acting ED drug, its absorption shows extensive variability with Tmax values ranging from 0.5 h to 12 h for a single 20 mg tadalafil dose. Despite the recommendation on the label to take Cialis® 30 minutes before sexual activity, only a minority of the patients reported successful intercourse attempts 30 mins after taking the highest approved 20 mg dose of Cialis®. In the same study 10 mg Cialis® failed to achieve its end-point for successful intercourse attempts within 30 mins over the placebo group.

Following oral administration of DRGT-99 immediate release tablets, maximum drug concentration was achieved on average 4 times faster than with 20 mg Cialis®.

Administering the 10 mg or 15 mg DRGT-99 tablet, drug exposure was more than 3-fold greater and variability was lower than for 20 mg Cialis® in the first 30 mins.

Time to achieve therapeutically effective plasma levels was also significantly shorter for DRGT-99 than for 20 mg Cialis®. Around half of the subjects taking 10 mg DRGT-99 reached therapeutically effective plasma levels in 15 mins and 100% by 30 mins. This number for 15 mg DRGT-99 was 72% and 100% respectively. Even 5 mg DRGT-99 resulted in therapeutically effective plasma levels in 73% of the subjects at 30 mins.

As for 20 mg Cialis® none of the subjects reached therapeutically effective plasma levels in 15 mins and only half of them at 30 mins.

Furthermore, reported adverse events for DRGT-99 were less frequent and less severe for all the dosage strengths tested than for 20 mg Cialis®. A potential safety advantage for DRGT-99.

“Our objective with DRGT-99 has been to develop the Best in Class ED drug that combines reliable, fast onset, longevity and improved side effect profile at the lowest possible dose” – said Gabor Heltovics, CEO of DRGT. “These encouraging results indicate that we are on track to do just that. We are advancing DRGT-99 to pivotal studies”- he added.

About DRGT

DRGT is a specialty pharmaceutical company dedicated to the development and commercialization of high-value proprietary drugs that deliver measurable and meaningful improvements in clinical utility.

DRGT utilizes its proprietary Super-API drug development platform to carefully select and screen drugs and develop their Super-API compositions. The Company’s Super-API portfolio contains 30 compounds in indications such as oncology, pain and erectile dysfunction with multi-$ billion potential. Super-API drugs are protected by global composition of matter IP.

DRGT is incorporated in Ireland with R&D facilities in Budapest, Hungary.

The corporation was founded by Dr. Ferenc Darvas, Chairman of the oldest Hungarian upstream-technology network.

Cialis and Viagra are registered trademarks of their respective owners.

Gábor Heltovics, CEO
E-mail: info@drgtco.com
Phone: +36-1-5779-300
http://www.drgtco.com

Postoperative urinary retention (POUR) refers to the inability to pass any urine despite a full bladder after surgery. It is a common complaint, occurring in up to 70% of surgical patients depending on the type of surgery. Individuals undergoing perineal, gynecologic, anorectal, inguinal, and lower urinary tract surgeries are at an increased risk for POUR. Additional risk factors include older age, male sex, prolonged surgery, spinal anesthesia, and early removal of urinary catheters.

The development of POUR has been associated with several negative outcomes, including pain, urinary tract infection (UTI), bladder dysfunction, kidney damage, increased length of hospital stays, elevated costs, and the need for additional surgeries. Urethral catheterization is the mainstay of management of POUR; however, catheterization alone can also increase the risk for UTI and extend hospital stays. For these reasons, pharmacotherapeutic approaches to prevention of POUR are needed.

At least eight clinical trials evaluating the safety and effectiveness of tamsulosin, a selective alpha-1 adrenergic receptor blocker, for prevention of POUR in male patients undergoing different types of surgery have been published to date. The results of these studies have been generally consistent, with six of the eight trials reporting a statistically significant reduction in the risk for POUR with tamsulosin versus placebo. The type of surgical patient and tamsulosin regimen studied in each of the identified trials are listed in the Table below. Three observational studies also have found positive outcomes associated with the use of tamsulosin in surgical settings.

Table. Characteristics of Clinical Research Assessing Tamsulosin Therapy for Prevention of POUR

Medical expulsive therapy using the alpha blocker tamsulosin does not aid passage of ureteral stones less than 9 mm in diameter, according to study findings published online in JAMA Internal Medicine.

In the double-blind STONE (Study of Tamsulosin for Urolithiasis in the Emergency Department) trial, investigators randomly assigned 512 emergency department patients (mean age 41; 27% female; 23% non-white) to 0.4 mg daily tamsulosin or placebo for 28 days. Stone passage rate did not differ significantly between groups (50% tamsulosin vs 47% placebo), Andrew Meltzer, MD, of George Washington University in Washington DC, and colleagues reported. In addition, the investigators observed no significant between-group differences with respect to time to stone passage, return to work time, analgesic use, hospitalization, need for surgery, or repeat visit to the emergency department.

For the study, patients could have stones in any part of the ureter. Stone size, location, and passage were confirmed by computed tomography.

Current guidelines by the American Urological Association recommend alpha blockers for ureteral stones 10 mm or less in diameter.

References

Meltzer AC, Katzen Burrows P, Wolfson AB, et al. Effect of tamsulosin on passage of symptomatic ureteral stones. JAMA Intern Med. doi:10.1001/jamainternmed.2018.2259 [Published online June 18, 2018]

Dahm P and Hollingsworth JM. Medical expulsive therapy for ureteral stones—Stone Age medicine. JAMA Intern Med. [Published online June 18, 2018]

Treatment with an α1adrenoceptor antagonist, tamsulosin, is associated with increased dementia risk among patients with symptomatic benign prostatic hyperplasia (BPH) aged ≥65 years, according to a Medicare data analysis published in Pharmacoepidemiology Drug Safety.

Using Medicare data from 2006 to 2012, investigators obtained patient data for men ≥65 years who were actively taking tamsulosin (n=253,136). These patients were compared with propensity-score-matched patients who did not use BPH medications (n=180,926), as well as patients who used doxazosin (n=28,581), terazosin (n=23,858), alfuzosin (n=17,934), dutasteride (n=34,027), and finasteride (n=38,767). Investigators used International Classification of Diseases, Ninth Revision, diagnosis codes to determine and compare incident dementia rates between each group.

A greater number of men in the tamsulosin group had dementia at the median 19.8-month follow-up compared with men who were not taking BPH medications (31.3 vs 25.9 per 1000 person-years, respectively; hazard ratio [HR], 1.17; 95% CI, 1.14-1.21; P <.001). In addition, patients taking tamsulosin had a significantly higher dementia risk than those taking doxazosin (HR, 1.20; 95% CI, 1.12-1.28; P<.001), terazosin (HR, 1.11; 95% CI, 1.04-1.19; P =.002), alfuzosin (HR, 1.12; 95% CI, 1.03-1.22; P =.010), dutasteride (HR, 1.26; 95% CI, 1.19-1.34; P <.001), and finasteride (HR, 1.13; 95% CI, 1.07-1.19; P <.001).

Prescribed drugs to help them urinate are a third more at risk of type 2 diabetes- Research shows

Men who take medication to reduce their symptoms of prostate disease may be more likely to develop type 2 diabetes, research suggests.

Patients with enlarged prostates who are prescribed drugs called 5-alpha-reductase inhibitors are around a third more at risk of the condition.

They reduce the production of androgens, a hormone which help to boost urinary flow, a common problem among men with enlarged prostates.

But these drugs – which include finasteride and dutasteride – may slow metabolism and reduce the body’s insulin sensitivity, which can trigger type 2 diabetes.

The research was carried out by the University of Edinburgh and University College London. It was led by Professor Ruth Andrew, a personal chair of pharmaceutical endocrinology at Edinburgh.

‘We found that commonly prescribed medications for prostate disease can increase risk of type 2 diabetes,’ Professor Andrew said.

The 5-alpha-reductase inhibitors are often prescribed to treat benign prostatic hyperplasia (BPH), the medical term for an enlarged prostate.

This becomes more common with age, with an estimated prevalence of between eight and 60 per cent in men aged 90.

To determine the health effects of the drug, the researchers analysed the health records of 55,275 men in the UK who had been prescribed 5-alpha-reductase inhibitors for their BPH over 11 years.

Results – published in the British Medical Journal – revealed the drugs raise a man’s risk of developing type 2 diabetes by around one-third.

Local pharmaceutical companies are preparing to release generic copies of Avodart (dutasteride), a treatment for enlarged prostate and hair loss, with reduced side effects.

The Ministry of Food and Drug Safety recently approved JW Pharmaceutical’s Jdart Tab., Dong-A ST’s Dutavan Plus Tab., Daehan New Pharm’s NPdart Tab., and JW Shinyak’s Neodart Tab.

These generics come in tablets, unlike Avodart and previous generics in soft capsules.

Soft capsules might be uncomfortable if they are stuck inside the mouth or the esophagus. The latest Avodart generics improved the patient convenience.

JW Pharm applied its technology called “self-micro emulsifying drug delivery system” (SMEDDS). SMEDDS converts insoluble agents to soluble ones, making body absorption quick.

The drugmaker unveiled the development of Jdart in March. It was the first in Korea to develop a dutasteride tablet.

JW Pharm completed the patent application for the dutasteride tablet in September last year. Dutasteride is effective in reducing urinary difficulties caused by enlarged prostate and acute cramps that make it difficult to release the urine. The agent is also known to prevent hair loss.

As Avodart’s patent expired in 2016, more than 30 generics have arrived in the market in severe competition.

GlaxoSmithKline, the supplier of Avodart, signed a contract with Teva-Handok to sell Avodart’s identical clone Zygard to counter attacks from generics.

To win the competition against the original treatment, Chong Kun Dang secured the generic exclusivity. Hanmi Pharmaceutical’s copy is only one-third of the size of Avodart.

With JW Pharm’s release of a similar tablet with minimized side effects, the competition in the Avodart-targeting market is likely to intensify.

lhs@docdocdoc.co.kr

Finasteride safely prevented prostate cancer, despite previous findings that suggested the drug increased the risk for high-grade disease, according long-term data published in The New England Journal of Medicine.

The latest results report mortality over 2 decades among men in the Prostate Cancer Prevention Trial, which previously found that finasteride reduced risk for prostate cancer by 24.8% compared with placebo.

However, trial results also showed that the drug increased the number of high-grade prostate cancers, leading to a warning label from the FDA. Although additional data showed finasteride improved detection of prostate cancer and high-grade prostate cancer by improving the performance characteristics of PSA testing, digital rectal examination and the prostate biopsy — which could explain the conflicting original results — questions regarding the risk of the drug persisted.

Finasteride, a 5-alpha-reductase inhibitor, also is used to treat lower urinary tract problems and male pattern baldness.

“The men most likely to benefit are those we see in the study — they are 55 years or older and are undergoing PSA testing,” Ian M. Thompson Jr., MD, chair of the genitourinary cancer committee for SWOG Cancer Research Network and president of CHRISTUS Santa Rosa Hospital Medical Center, told HemOnc Today. “The magnitude of the benefit may be greater in men who are at higher risk for prostate cancer, that being a man with a family history or an African-American man. … But what we found in the original study is that all men — regardless of family history, race, ethnicity and so forth — have a risk reduction.”

Researchers of the trial randomly assigned 18,882 men — enrolled from 1993 to 1997 — to receive finasteride or a placebo for 7 years.

At median follow-up of 18.4 years, 42 men in the finasteride group and 56 men in the placebo group had died of prostate cancer.

The 25% lower risk for prostate cancer death with finasteride was not statistically significant (HR = 0.75; 95% CI, 0.5–1.12).

However, Thompson said the results eliminate concerns about the possible risk for more aggressive cancers with finasteride, which he described as an inexpensive and reliable prostate cancer prevention drug.

He said that he is unaware of a clear process that would take the warning label off the drug.

“But it’s not just changing the warning. It’s also putting in the label that this drug results in an unequivocal reduction in the risk for cancer,” Thompson told HemOnc Today. “This is really a big deal. … If we had known this at the time the study was originally published, my suspicion is that many or most men who are [aged] 55 years or older would be taking this medication. But because it had a stain on it … it’s kind of like a sticky fact. The trick will be helping the community get rid of that sticky fact and go back to this original discovery.

“This is the most common cancer in men,” Thompson added. “If men at risk for prostate cancer took this, we could eliminate 40,000 to 50,000 prostate cancer [diagnoses] a year, and that’s a huge deal from a cost and suffering standpoint.” – by John DeRosier

For more information:

Ian M. Thompson Jr., MD, can be reached at: ian.thompson2@christushealth.org.

Disclosures: The NCI and NIH funded this study. Thompson reports no relevant financial disclosures. Please see the study for all other authors’ relevant financial disclosures.

(HealthDay News) — Finasteride is not associated with an increased risk for death due to prostate cancer, according to a research letter published in the New England Journal of Medicine.

Noting that a previous trial showed that finasteride was associated with a reduced risk for prostate cancer compared with placebo but a higher risk for high-grade cancer, Phyllis J. Goodman, from the Fred Hutchinson Cancer Research Center in Seattle, and colleagues examined whether finasteride would lead to an increase in prostate cancer mortality. To address this question, the authors calculated the cumulative incidence of death from prostate cancer among all participants who underwent randomization.

The researchers found that during 296,842 person-years of follow-up and a median follow-up of 18.4 years, there were 3048 deaths in 9423 men randomly assigned to finasteride (42 due to prostate cancer) and 2979 deaths in 9457 men randomly assigned to placebo (56 due to prostate cancer). The 25% lower risk for death from prostate cancer with finasteride was not statistically significant because of the small number of deaths from prostate cancer.

“The early concerns regarding an association between finasteride and an increased risk of high-grade prostate cancer have not been borne out,” the authors write.

Reference

Goodman PJ. Long-Term Effects of Finasteride on Prostate Cancer Mortality. N Engl J Med 2019; 380:393-394. DOI:10.1056/NEJMc1809961